Is SCHD a Good ETF to Buy?
With around $65.7 billion in net assets, Schwab’s US Dividend…
Sell
16
KALV Quote, Financials, Valuation and Earnings
Last price:
$8.71
Seasonality move
:
-3.06%
Day range:
$8.62 - $9.10
52-week range:
$7.97 - $16.88
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
29.26x
P/B ratio:
3.20x
Volume:
182.2K
Avg. volume:
376.9K
1-year change:
-23.66%
Market cap:
$428.9M
Revenue:
--
EPS (TTM):
-$3.69
Analysts' Opinion
-
Consensus RatingKalVista Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $28.50, KalVista Pharmaceuticals has an estimated upside of 217.64% from its current price of $8.68.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $18.00 representing 100% downside risk from its current price of $8.68.
Fair Value
-
According to the consensus of 5 analysts, KalVista Pharmaceuticals has 217.64% upside to fair value with a price target of $28.50 per share.
KALV vs. S&P 500
-
Over the past 5 trading days, KalVista Pharmaceuticals has overperformed the S&P 500 by 0.16% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
KalVista Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
KalVista Pharmaceuticals has grown year-over-year revenues for 1 quarter straight. In the most recent quarter KalVista Pharmaceuticals reported revenues of --.
Earnings Growth
-
KalVista Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter KalVista Pharmaceuticals reported earnings per share of -$0.91.
Enterprise value:
293.2M
EV / Invested capital:
--
Price / LTM sales:
29.26x
EV / EBIT:
--
EV / Revenue:
23.10x
PEG ratio (5yr expected):
-0.32x
EV / Free cash flow:
-2.38x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-10-31 | 2023-10-31 | 2024-10-31 | 2023-10-31 | 2024-10-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$90.4M | -$101.7M | -$163.2M | -$29.7M | -$45.8M | |
| EBITDA | -$89.8M | -$101M | -$162.3M | -$29.5M | -$45.6M | |
| Diluted EPS | -$3.74 | -$3.06 | -$3.69 | -$0.80 | -$0.91 | |
| Period Ending | 2020-10-31 | 2021-10-31 | 2022-10-31 | 2023-10-31 | 2024-10-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $72.1M | $234.5M | $151.2M | $128.6M | $152.3M | |
| Total Assets | $75.4M | $243.8M | $162.8M | $138.7M | $160.8M | |
| Current Liabilities | $9.5M | $10.1M | $11.3M | $17.8M | $22.2M | |
| Total Liabilities | $10.5M | $16.3M | $19M | $24.3M | $26.8M | |
| Total Equity | $65M | $227.5M | $143.8M | $114.4M | $134M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-10-31 | 2023-10-31 | 2024-10-31 | 2023-10-31 | 2024-10-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$84.2M | -$78.5M | -$122.5M | -$19.8M | -$39.6M | |
| Cash From Investing | $75.5M | $39.4M | -$47.1M | $28.6M | $48.7M | |
| Cash From Financing | $1.2M | $58.1M | $153.7M | $128K | $295K | |
| Free Cash Flow | -$85.6M | -$78.8M | -$123.1M | -$20M | -$39.8M | |
KALV
Sector
Market Cap
$428.9M
$48.9M
Price % of 52-Week High
51.42%
49.34%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-23.66%
-30.56%
Beta (5-Year)
0.859
0.754
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$8.69
200-day SMA
Sell
Level
$11.49
Bollinger Bands (100)
Sell
Level
9.34 - 12.2
Chaikin Money Flow
Sell
Level
-36.4M
20-day SMA
Sell
Level
$8.80
Relative Strength Index (RSI14)
Sell
Level
44.39
ADX Line
Buy
Level
16.39
Williams %R
Neutral
Level
-46.6165
50-day SMA
Sell
Level
$9.79
MACD (12, 26)
Sell
Level
-0.30
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Neutral
Level
36.1M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (7)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
Stock Forecast FAQ
In the current month, KALV has received 5 Buy ratings 0 Hold ratings, and 0 Sell ratings. The KALV average analyst price target in the past 3 months is $28.50.
-
Where Will KalVista Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that KalVista Pharmaceuticals share price will rise to $28.50 per share over the next 12 months.
-
What Do Analysts Say About KalVista Pharmaceuticals?
Analysts are divided on their view about KalVista Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that KalVista Pharmaceuticals is a Sell and believe this share price will drop from its current level to $18.00.
-
What Is KalVista Pharmaceuticals's Price Target?
The price target for KalVista Pharmaceuticals over the next 1-year time period is forecast to be $28.50 according to 5 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is KALV A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for KalVista Pharmaceuticals is a Buy. 5 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of KALV?
You can purchase shares of KalVista Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase KalVista Pharmaceuticals shares.
-
What Is The KalVista Pharmaceuticals Share Price Today?
KalVista Pharmaceuticals was last trading at $8.71 per share. This represents the most recent stock quote for KalVista Pharmaceuticals. Yesterday, KalVista Pharmaceuticals closed at $8.68 per share.
-
How To Buy KalVista Pharmaceuticals Stock Online?
In order to purchase KalVista Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is NAIL a Good ETF to Buy?
If you’re thinking about buying the NAIL ETF, this article…
3 High Dividend Dow Jones Stocks
Thanks to surging stock prices over the past two years,…
Stock Ideas
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 125x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
NARI alert for Jan 7
Inari Medical [NARI] is up 22.25% over the past day.
Buy
70
PDEX alert for Jan 7
Pro-Dex [PDEX] is down 10.89% over the past day.
Buy
52
ALCO alert for Jan 7
Alico [ALCO] is down 3.89% over the past day.
